KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CRISPR Therapeutics AG (CRSP) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q3 2025 value amounting to -$1.17.

  • CRISPR Therapeutics AG's EPS (Basic) fell 1584.16% to -$1.17 in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.57, marking a year-over-year decrease of 9892.86%. This contributed to the annual value of -$4.84 for FY2024, which is 14928.28% down from last year.
  • Latest data reveals that CRISPR Therapeutics AG reported EPS (Basic) of -$1.17 as of Q3 2025, which was down 1584.16% from -$2.4 recorded in Q2 2025.
  • In the past 5 years, CRISPR Therapeutics AG's EPS (Basic) ranged from a high of $10.01 in Q2 2021 and a low of -$2.4 during Q2 2022
  • For the 5-year period, CRISPR Therapeutics AG's EPS (Basic) averaged around -$0.81, with its median value being -$1.43 (2024).
  • Its EPS (Basic) has fluctuated over the past 5 years, first surged by 87000.0% in 2021, then crashed by 18288.84% in 2024.
  • Quarter analysis of 5 years shows CRISPR Therapeutics AG's EPS (Basic) stood at -$1.88 in 2021, then rose by 25.53% to -$1.4 in 2022, then soared by 180.71% to $1.13 in 2023, then tumbled by 182.89% to -$0.94 in 2024, then decreased by 24.91% to -$1.17 in 2025.
  • Its EPS (Basic) stands at -$1.17 for Q3 2025, versus -$2.4 for Q2 2025 and -$1.58 for Q1 2025.